Benzinga | Oct 29, 2020 07:36AM EDT

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8



* Immatics' first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics

* The IMA401 target, an HLA-A*02-bound peptide derived both from MAGEA4 and MAGEA8, shows >5-fold higher target peptide levels on cancer cells than a commonly used target peptide derived from MAGEA4

* Immatics continues to anticipate submission of an IND application for IMA401 by the end of 2021